Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncorena in connection with share issue
Mandate

Vinge advises Oncorena in connection with share issue

July 30, 2025 Capital Markets and Public M&A Life Sciences & Health

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.

The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026